Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01855698 | PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism | completed | — | 99 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00113646 | Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 14 | Massachusetts General HospitalOTHER | 1 | Mar 16, 2018 |
| clinicaltrials |
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | completed | Phase 1 / Phase 2 | 177 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 65 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01547806 | Collection of Transplant Stem Cells for Plasma Cell Myeloma | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | completed | Phase 1 / Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | completed | — | 110 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00287872 | Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00375791 | Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | completed | Phase 2 | 67 | AEterna ZentarisINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT02033928 | Comprehensive Frailty Assessment | completed | — | 111 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00401011 | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 84 | AEterna ZentarisINDUSTRY | 0 | Feb 23, 2018 | clinicaltrials |
| NCT00400686 | Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | completed | N/A | 31 | The Cleveland ClinicOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01241292 | Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 15, 2018 | clinicaltrials |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | completed | Phase 2 | 13 | Incyte CorporationINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT01315873 | Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | terminated | Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01675141 | Lenalidomide Maintenance Therapy for Multiple Myeloma | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00891384 | Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 194 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00185614 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | completed | Phase 2 | 63 | Wen-Kai WengOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03402295 | Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation(GBRAM003r) | completed | Phase 3 | 311 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 0 | Jan 18, 2018 | clinicaltrials |
| NCT01472627 | Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro | completed | — | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00963820 | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02220608 | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT01270932 | Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01332617 | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | withdrawn | Phase 2 | 0 | University of LouisvilleOTHER | 0 | Dec 29, 2017 | clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01083602 | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma(MACS1271) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2017 | clinicaltrials |
| NCT00461045 | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 15 | CelgeneINDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03373526 | Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation | unknown | N/A | 50 | Daniel Godoy MartinezOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00349778 | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | completed | Phase 2 | 102 | Stanford UniversityOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01057225 | Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Mayo ClinicOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00686556 | Total Marrow Irradiation for Refractory Acute Leukemia | completed | Phase 1 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00602693 | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | completed | Phase 1 | 41 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | terminated | Phase 2 | 13 | University of Southern CaliforniaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 1 | Emory UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 22, 2018source: clinicaltrials